je.st
news
Tag: vaccine
GSK hails Ebola vaccine breakthrough
2014-11-26 23:00:03| BBC News | Business | UK Edition
Sir Andrew Witty says "tantalising" prospect of viable vaccine becoming available next year
Tags: breakthrough
vaccine
hails
gsk
MSD Animal Health Receives Approval for Porcilis PCV M Hyo Vaccine in Europe
2014-11-25 01:00:00| ThePigSite - Industry News
EU - MSD Animal Health says the European Commission has approved its PORCILIS® PCV M Hyo vaccine that protects piglets against Porcine Circovirus and Mycoplasma hyopneumoniae infections.
Tags: health
europe
animal
approval
Merck, Iowa firm sign Ebola vaccine licensing deal
2014-11-24 20:15:55| Biotech - Topix.net
Merck & Co., one of the world's top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing. The exclusive deal involves a vaccine candidate called rVSV-EBOV that's under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa.
Merck Partners With NewLink To Speed Up Work On Ebola Vaccine
2014-11-24 20:15:54| Biotech - Topix.net
A 26-year-old man receives an injection in September of an experimental Ebola vaccine being tested by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Until now, the two leading candidates for a vaccine to protect against the Ebola virus were being led by global pharmaceutical giant GlaxoSmithKline on the one hand, and a tiny company in Ames, Iowa, that was virtually unknown, on the other.
Tags: work
speed
partners
vaccine
Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
2014-11-24 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. & AMES, IA Clinical Development, Manufacturing Expertise, and Scale Critical to Success WHITEHOUSE STATION, N.J. & AMES, IA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLinks investigational rVSV-EBOV (Ebola) vaccine candidate. Language: English Contact: Merck Media Contacts:Pam Eisele, 267-305-3558Imraan Munshi, 215-652-0059orInvestor Contacts:NewLink GeneticsJack Henneman, 515-598-2561orMerckJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: NLNK Exchange: NASDAQ read more
Tags: enter
agreement
collaboration
licensing
Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »